RxDoctor Payments Data

Mark Pulsipher, MD

Interventional Cardiology · St George, UTNPI 1689631913

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Abiomed at 37.9% of the total. Reporting peaked in 2021 at $167 and has fallen 72.9% since, to $45 in 2025. That places this record below the midpoint for interventional cardiology clinicians in UT, where the typical reported total is $5,946.

$391in general payments, 2019–2025

Across 14 payments — averaging $27.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$148
  • Boston Scientific$108
  • Novartis$33
  • Amgen$26
  • Johnson & Johnson$24
  • Shockwave Medical, Inc$22
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$391100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$391 in reported general payments places this provider in the 5th percentile of 45 interventional cardiology providers in Utah.

See all interventional cardiology providers in Utah

Medicare billing

Part B allowed, 2024
$167,547
Medicare patients
1,537
Services billed
2,220

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban155$215,550
XareltoRivaroxaban38$55,813
Repatha SureclickEvolocumab43$34,256
JardianceEmpagliflozin28$32,537
Repatha SyringeEvolocumab14$14,073
Rosuvastatin Calcium441$7,951
Ezetimibe231$7,900
Metoprolol Succinate356$5,238
Atorvastatin Calcium407$4,554
Amlodipine Besylate318$2,820
ClopidogrelClopidogrel Bisulfate223$2,819
Lisinopril207$1,846
Losartan Potassium112$1,577
Valsartan34$1,533
Olmesartan Medoxomil65$1,430

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$24$55,81338 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 45 interventional cardiology providers in Utah.

Other interventional cardiology in St George

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →